Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01884636 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01884636 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 24 participants.
The verdict
NCT01884636, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of methotrexate. Safety and tolerability of isavuconazole will be assessed alone and in combination with methotrexate.
Interventions
- DRUG methotrexate
- DRUG isavuconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01884636
The ClinicalTrials.gov registry entry for NCT01884636 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which methotrexate is the first listed.
NCT01884636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01884636 about?
NCT01884636 is a clinical study titled "A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate". The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of methotrexate. Safety and tolerability of isavuconazole will be assessed alone and in combination with methotrexate.
What is the current status of trial NCT01884636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01884636?
The interventions under investigation include: methotrexate (DRUG), isavuconazole (DRUG).
Who is sponsoring clinical trial NCT01884636?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.